AstraZeneca has announced that it has begun a pre-clinical development programme to evaluate the ability of investigational antibody, MEDI 2452,...
AstraZeneca has announced the start of the Phase III programme for MEDI 4736, an immunotherapy in development for the treatment...
AstraZeneca has halted enrolment in two trials (Phase I TATTON and Phase III CAURAL studies) of combination AZD 9291 (mereletinib)...
Results from pivotal Phase III trials demonstrated that adding MEDI 563 (benralizumab), from Medimmune/Astrazeneca, to standard-of-care medicine significantly reduced exacerbations...
Results from the Phase III ZONDA trial of MEDI 563 (benralizumab), from AstraZeneca, demonstrated that adding benralizumab to standard of...
AstraZeneca has announced that MEDI 563 (benralizumab) was well tolerated and achieved the primary endpoint in two pivotal Phase III...
Results from a prespecified pooled analysis of the pivotal Phase III MELODY and Phase IIb trials of MEDI 8897 (nirsevimab) from Sanofi and AstraZeneca demonstrated an efficacy (relative risk reduction versus placebo) of 79.5% (95% CI 65.9 to 87.7; P<0.0001) against medically attended lrti, such as bronchiolitis or pneumonia, caused by rsv in infants born at term or preterm entering their first rsv season.
Arcutis Biotherapeutics, Inc. announced the launch of an educational campaign designed to elevate understanding, connection, and encouragement for those living with seborrheic dermatitis, or Seb Derm for short
AstraZeneca will recover the global rights to brazikumab (formerly MEDI 2070), a monoclonal antibody targeting IL23, from Allergan. Brazikumab is...